The primary marker of the mesenchymal phenotype is N-cadherin, encoded by the CDH2 gene [9], along with vimentin (encoded by VIM), beta-catenin (gene CTNNB1), Lymphoid Enhancer Binding Factor 1 (LEF1), and NOTCH1. Additional genes encoding EMT-TFs were also included in the study, SOX2, TWIST1, SNAI1, SNAI2, ZEB1, and ZEB2. EMT also plays a role in glioma tumors. This evidence concerns the gene LEF1 and central nervous system cancer.